This document is an excerpt from the EUR-Lex website
Document 62014TN0511
Case T-511/14: Action brought on 2 July 2014 — Novartis Europharm v Commission
Case T-511/14: Action brought on 2 July 2014 — Novartis Europharm v Commission
Case T-511/14: Action brought on 2 July 2014 — Novartis Europharm v Commission
IO C 388, 3.11.2014, p. 17–18
(BG, ES, CS, DA, DE, ET, EL, EN, FR, HR, IT, LV, LT, HU, MT, NL, PL, PT, RO, SK, SL, FI, SV)
|
3.11.2014 |
EN |
Official Journal of the European Union |
C 388/17 |
Action brought on 2 July 2014 — Novartis Europharm v Commission
(Case T-511/14)
2014/C 388/21
Language of the case: English
Parties
Applicant: Novartis Europharm Ltd (Horsham, United Kingdom) (represented by: C. Schoonderbeek, lawyer)
Defendant: European Commission
Form of order sought
The applicant claims that the Court should:
|
— |
annul the contested decision; and |
|
— |
order the European Commission to pay its own costs and those of Novartis. |
Pleas in law and main arguments
By its present action, the applicant seeks the annulment of Commission Decision C (2014) 2155 final of 27 March 2014 granting a marketing authorisation to Teva Generics for the medicinal product for human use ‘Zoledronic acid Teva Generics — Zoledronic Acid’.
In support of the action, the applicant relies on a single plea in law, essentially identical or similar to the plea in law relied on in Cases T-472/12 Novartis Europharm v Commission (1) and T-67/13 Novartis Europharm v Commission (2).